Stock listing

NASDAQ:EIKN Eikon Therapeutics, Inc. Stock

Home listing (NASDAQ) of Eikon Therapeutics, Inc.

Follow Eikon Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:EIKN

$4.74 USD -0.43 (-8.3%)

Close on Nov 20, 2026

Since Feb 5, 2026 -68.4% · daily closes, Feb 5, 2026 – Nov 20, 2026, adjusted for splits
Day range
$4.74 – $5.19 USDNov 20, 2026
Volume
691,438 sharesNov 20, 2026
Market cap
$256.8M USDAt the close on Nov 20, 2026 · price × 54.19M shares outstanding
Traded on an average day
$4.45M USDMedian day 532,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Eikon Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:EIKN · Home$4.74 USD-0.43 (-8.3%)691,438$4.85$5.19$4.74$5.17Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EIKN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.74-0.43-8.3%$4.85$5.19$4.74691,438
$5.17+0.02+0.4%$5.11$5.38$5.02392,298
$5.15-0.235-4.4%$5.39$5.39$4.95477,037
$5.385-0.595-9.9%$5.97$6.19$5.27496,234
$5.98-0.06-1.0%$6.06$6.10$5.585294,007
$6.04-0.63-9.4%$6.68$6.725$5.84735,487
$6.67+0.54+8.8%$6.08$6.81$6.08439,191
$6.13+0.26+4.4%$5.87$6.33$5.73424,891
$5.87-0.03-0.5%$6.03$6.04$5.62722,194
$5.90+0.06+1.0%$5.79$6.065$5.63401,467
$5.84-0.55-8.6%$6.39$6.43$5.75787,738
$6.39+0.84+15.1%$5.69$6.42$5.36658,571
$5.55-0.13-2.3%$5.68$6.018$5.35556,047
$5.68+0.37+7.0%$5.35$5.755$5.21409,342
$5.31-0.04-0.7%$5.27$5.40$5.01552,600
$5.35-0.19-3.4%$5.69$5.83$5.28574,800
$5.54-0.01-0.2%$5.49$5.71$5.32660,600
$5.55+0.01+0.2%$5.56$5.99$5.51697,200
$5.54-1.72-23.7%$7.20$7.44$5.44965,600
$7.26-0.98-11.9%$8.07$8.07$7.20318,400
$8.24+0.24+3.0%$7.98$8.29$7.93348,500
$8.00-0.18-2.2%$8.12$8.40$7.97240,700
$8.18+0.48+6.2%$7.75$8.48$7.67336,400
$7.70+0.28+3.8%$7.45$8.21$7.13700,900
$7.42-0.12-1.6%$7.73$7.76$7.19482,800
$7.54+0.53+7.6%$7.01$7.69$7.01654,400
$7.01+0.29+4.3%$6.69$7.07$6.45595,500
$6.72-0.54-7.4%$7.19$7.30$6.71406,700
$7.26-0.21-2.8%$7.45$7.60$7.16236,200
$7.47-0.03-0.4%$7.48$7.82$7.25288,700
$7.50-0.04-0.5%$7.48$7.74$7.19847,100
$7.54+0.03+0.4%$7.32$7.63$7.11920,200
$7.51-0.03-0.4%$7.67$7.84$7.43610,800
$7.54+0.21+2.9%$7.42$7.66$7.02485,300
$7.33-0.08-1.1%$7.55$7.55$7.07420,400
$7.41-0.63-7.8%$8.00$8.09$7.40624,600
$8.04+0.13+1.6%$7.95$8.16$7.71585,800
$7.910.000.0%$7.88$8.10$7.80334,800
$7.91-0.01-0.1%$7.81$8.00$7.55435,000
$7.92-0.37-4.5%$8.45$8.47$7.87377,100
$8.29+0.16+2.0%$8.14$8.40$7.72710,000
$8.13-0.85-9.5%$8.94$8.94$7.96727,300
$8.98+0.15+1.7%$8.97$9.33$8.75430,700
$8.83-0.12-1.3%$9.06$9.16$8.65463,900
$8.95+0.35+4.1%$8.70$9.09$8.652,242,400
$8.60+0.09+1.1%$8.65$9.33$8.57640,200
$8.51-0.98-10.3%$9.47$9.64$8.39989,400
$9.49+0.13+1.4%$9.33$10.24$9.08843,400
$9.36+0.42+4.7%$8.95$9.44$8.93713,100
$8.94-0.27-2.9%$9.28$9.56$8.791,010,200
$9.21-1.52-14.2%$10.65$10.68$9.17665,100
$10.73+0.02+0.2%$11.01$11.47$10.63752,400
$10.71-0.15-1.4%$10.81$11.03$10.61462,300
$10.86-0.10-0.9%$10.81$11.05$10.62238,700
$10.96-0.42-3.7%$11.45$11.66$10.91384,300
$11.38+0.50+4.6%$10.91$11.67$10.65552,800
$10.88+0.42+4.0%$10.31$10.94$10.10333,500
$10.46-0.52-4.7%$10.89$10.91$10.45290,700
$10.98-0.54-4.7%$11.41$11.45$10.90239,600
$11.52-0.46-3.8%$11.97$12.24$11.46261,700
$11.98-0.57-4.5%$12.56$13.00$11.90324,100
$12.55+1.39+12.5%$11.26$12.82$11.24567,204
$11.16-0.23-2.0%$11.59$11.92$10.94398,364
$11.39+0.64+6.0%$10.87$12.11$10.75532,800
$10.75-1.26-10.5%$11.90$12.04$10.40559,700
Ticker
NASDAQ:EIKN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Eikon Therapeutics, Inc. news

Eikon Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 22 in all · newest Nov 17, 2026 · oldest 2026
Decks
4 decks · latest November 2026

Where Eikon Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:EIKN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:EIKNBOATSUnited StatesUSD
BX Swiss:EIKNBX SwissSwitzerlandCHF

Valuation

Price/book 0.7× against a median of 2.0×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$44.67M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.7×
Beta vs S&P 500
1.91

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
Kyverna Therapeutics, Inc. · NASDAQ:KYTXUS$263.5MUS$117.8Mn/an/an/a2.0×n/a0.2×2.02
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
Ocugen, Inc. · NASDAQ:OCGNUS$260.6MUS$178.1Mn/a37.3×n/an/an/an/a1.47
Altimmune, Inc. · NASDAQ:ALTUS$258.8MUS$28.73Mn/an/an/a0.6×n/a0.1×1.55
Prelude Therapeutics Incorporated · NASDAQ:PRLDUS$258.6MUS$136.2Mn/a6.3×n/a2.1×−247.1%0.1×1.48
OBI Pharma, Inc. · TPEX:4174US$258.4MUS$243.4Mn/a154×n/a5.7×n/a0.0×n/a
TransThera Sciences (Nanjing). Inc. · HKEX:2617US$257.1MUS$119.1Mn/an/an/a1.9×n/a0.0×n/a
SAB Biotherapeutics, Inc. · NASDAQ:SABSUS$255.7MUS$156.5Mn/an/an/a1.2×n/a0.0×1.19
Evommune, Inc. · NYSE:EVMNUS$255.5MUS$86.86Mn/an/an/a1.0×n/a0.0×0.96
Editas Medicine, Inc. · NASDAQ:EDITUS$253.1MUS$119.7Mn/a2.4×n/a3.0×−144.9%0.7×2.22
Median of the othersUS$258.5MUS$128.0M21.8×2.0×−196.0%0.1×1.48

Forecasts

4 strong buy · 2 buy · 1 strong sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
24.33 USD · Analysts' mean
EPS, year to Dec 2026
-6.45 · 6 analysts

Team and board

Officers

OfficerRole
Roger PerlmutterChief Executive Officer
Alfred BowieChief Financial Officer
Mike KlobucharChief Operating Officer
Ben ThornerChief Business Officer and General Counsel
Ching-Pin ChangExecutive Vice President and Chief Scientific Officer
Barbara HowesChief People Officer
Roy BaynesChief Medical Officer
Russ BermanChief Technology Officer

Board

DirectorRole
Alfred BowieChief Financial Officer
Barbara HowesChief People Officer
Ma. Fatima D. FranciscoDirector
Roger PerlmutterChief Executive Officer
Roy BaynesChief Medical Officer

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−9.4%
Q2 2026Aug 13, 2026 · After close+7.0%
Q1 2026May 11, 2026 · After close+15.9%
Q4 2025Mar 30, 2026+7.8%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update56 slidesNovember 2026
Corporate Update (August 2026)Corporate update33 slidesAug 14, 2026
Corporate Update (June 2026)Corporate update49 slidesJun 1, 2026
Q2 2026 Earnings PresentationEarnings34 slidesMay 11, 2026

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: about US$381M · US$18 a share · J.P. Morgan +4
Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), BofA Securities (co-lead), Cantor (co-lead), Mizuho (co-lead)
Feb 5, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Feb 4, 2026.

Price
US$18.00 a share
Shares offered
21,177,600 shares of common stock
Offering size
US$381.2 million
Underwriters' option
Up to 3,176,640 more shares
Listing
EIKN on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, Mizuho · In the order on the cover
Shares delivered
On or about Feb 6, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceMay 9, 2025
Filed publiclyJan 9, 2026
Amended onceJan 28, 2026
Shares registered with an exchangeJan 28, 2026
Declared effective by the SECJan 30, 2026
Final prospectus, with the priceFeb 5, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Feb 5, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue000
Cost of revenue24.2M
Gross profit-24.2M
Research and development250.3M204.5M207.3M
Selling, general and administrative88.6M55.8M58.5M
Operating income-338.9M-260.3M-265.7M
Depreciation and amortization24.2M25.4M17.7M
EBITDA-314.8M-235.0M-248.0M
Interest expense837.0K31.0K39.0K
Income before tax-324.2M-243.8M-242.0M
Net income-324.2M-243.8M-242.0M
Earnings per share, basic-5.99-4.52-4.48

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents104.9M129.2M112.8M
Short-term investments231.1M90.9M317.6M
Current assets348.9M227.9M436.4M
Total assets594.7M491.2M525.7M
Accounts payable681.0K17.6M2.19M
Current liabilities55.0M56.4M31.4M
Total debt257.3M
Total liabilities1.47B1.06B867.1M
Shareholders' equity-879.0M-571.9M-341.4M
Shares outstanding54.1M54.0M54.0M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-188.5M-134.8M-190.8M
Capital spending-46.7M-84.8M-28.5M
Free cash flow-235.3M-219.6M-219.4M
Cash from investing-181.3M
Cash from financing352.1M244.0K105.8M
Change in cash-17.8M16.8M51.9M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
8-K · Current reportOct 26, 2026Current reportSEC
8-K · Current reportOct 23, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 2, 2026Big-stake noticeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
8-K · Current reportAug 13, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
All 69 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
8-K · Current reportAug 3, 2026Management or board changeSEC
3 · Initial statement of ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Management or board changeSEC
8-K · Current reportJun 1, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
8-K · Current reportMar 30, 2026ResultsSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 6, 2026Offer documentSEC
8-K · Current reportFeb 6, 2026Current reportSEC
424B4 · ProspectusFeb 5, 2026Offer documentSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 4, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringFeb 4, 2026Offer documentSEC
CERT · Exchange's certificate of listingFeb 4, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeJan 28, 2026Other filingsSEC
S-1/A · Registration statement, amendedJan 28, 2026Offer documentSEC
S-1 · Registration statementJan 9, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedDec 12, 2025Offer documentSEC
DRS/A · Draft registration statement, amendedSep 26, 2025Offer documentSEC
DRS/A · Draft registration statement, amendedJun 30, 2025Offer documentSEC
DRS · Draft registration statementMay 9, 2025Offer documentSEC
DFeb 28, 2025Other filingsSEC
DJun 1, 2023Other filingsSEC
DJan 6, 2022Other filingsSEC
DMay 13, 2021Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Eikon Therapeutics, Inc.’s releases · as of Nov 2, 2026

Common shares
54,186,095
Fully diluted
54,186,095

Fully diluted

LineSharesAs of
Common shares54,186,095Nov 2, 2026

Share count over time

CountShares
Nov 2, 202654,186,095

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Fidelity5.52M10.2%US$44.4M+526KNov 10, 2026
BlackRock4.87M9.0%US$39.1M+588KNov 13, 2026
T. Rowe Price2.75M5.1%US$22.1M+148KNov 16, 2026
Foresite Capital Management IV, LLC1.94M3.6%US$15.6MNo changeNov 16, 2026
Merck & Co., Inc.1.67M3.1%US$13.4MNo changeNov 13, 2026
Vanguard1.45M2.7%US$11.7M+224KNov 13, 2026
Foresite Capital Management V, LLC1.32M2.4%US$10.6MNo changeNov 16, 2026
Capital Group1.18M2.2%US$9.45MNo changeNov 12, 2026
AllianceBernstein1.05M1.9%US$8.46M+410KNov 16, 2026
EcoR1 Capital, LLC856K1.6%US$6.88M+123KNov 16, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Geode Capital754K1.4%US$6.07M+198KNov 6, 2026
Regents Of The University Of California635K1.2%US$5.11MNewOct 26, 2026
State Street609K1.1%US$4.9M+255KNov 12, 2026
Baker Bros. Advisors LP556K1.0%US$4.47MNo changeNov 16, 2026
StepStone Group LP523K0.97%US$4.21M+128KNov 17, 2026
Soros Capital Management LLC485K0.89%US$3.9MNo changeNov 13, 2026
Millennium419K0.77%US$3.37M+286KNov 16, 2026
Walleye Capital LLC391K0.72%US$3.15MNewNov 13, 2026
CPP Investments379K0.70%US$3.05MNo changeNov 16, 2026
Citadel354K0.65%US$2.85M+341KNov 16, 2026
Franklin Templeton350K0.65%US$2.24MNo changeNov 12, 2026
Affinity Asset Advisors, LLC298K0.55%US$2.4M+200KNov 13, 2026
UBS279K0.51%US$2.24M+15,102Nov 16, 2026
BNP Paribas272K0.50%US$2.19M+129KNov 12, 2026
Schwab260K0.48%US$2.09M+77,426Nov 16, 2026
Morgan Stanley247K0.46%US$1.99M+235KNov 13, 2026
Northern Trust246K0.45%US$1.98M+70,089Nov 16, 2026
Two Sigma184K0.34%US$1.48MNewNov 16, 2026
Woodline Partners LP162K0.30%US$1.3MNewNov 16, 2026
Ensign Peak Advisors, Inc142K0.26%US$1.15M−27,992Nov 12, 2026
Comprehensive Financial Management LLC141K0.26%US$1.13M+24,580Nov 16, 2026
Bank of America137K0.25%US$1.11M+99,882Nov 16, 2026
XTX Topco Ltd133K0.25%US$1.07M+106KNov 16, 2026
Goldman Sachs128K0.24%US$1.03MNewNov 16, 2026
Alps Advisors Inc71,2550.13%US$573K+16,307Nov 2, 2026
BNY65,8710.12%US$530K+18,083Nov 5, 2026
Los Angeles Capital Management LLC63,8300.12%US$513KNewNov 12, 2026
Aquatic Capital Management LLC62,8830.12%US$506KNewNov 16, 2026
JPMorgan56,9510.11%US$450K+46,627Nov 12, 2026
AQR Capital Management LLC52,4920.10%US$422KNewNov 16, 2026
Invesco51,1580.09%US$411K+258Nov 12, 2026
Trexquant Investment LP48,5000.09%US$390KNewNov 16, 2026
EntryPoint Capital, LLC47,9430.09%US$385KNewNov 13, 2026
Nuveen46,3120.09%US$372K+17,324Nov 10, 2026
D. E. Shaw & Co., Inc.39,2400.07%US$315KNewNov 16, 2026
TCG Crossover Management, LLC37,9020.07%US$305KNo changeNov 16, 2026
DCF Advisers, LLC33,7920.06%US$272KNewNov 4, 2026
Quadrature Capital Ltd28,3990.05%US$228KNewNov 13, 2026
Rhumbline Advisers27,8560.05%US$224K+3,373Nov 10, 2026
DWS27,2300.05%US$219K+5,708Nov 6, 2026

This page holds 50 of 92 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Contrafund1.28M2.4%US$16.6MNo changeJun 30, 2026
SMALLCAP World Fund Inc1.14M2.1%US$14.9MNo changeJun 30, 2026
Select Biotechnology Portfolio974K1.8%US$10.6M+669KMay 31, 2026
T. Rowe Price Small-Cap Value Fund, Inc.926K1.7%US$12.1M+208KJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio722K1.3%US$7.83MNo changeMay 29, 2026
Vanguard Total Stock Market Index Fund660K1.2%US$8.61M−51,800Jun 30, 2026
Fidelity Growth Company Fund602K1.1%US$6.53M+166KMay 31, 2026
iShares Russell 2000 ETF511K0.94%US$6.66MNewJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.349K0.64%US$4.56MNo changeJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.331K0.61%US$4.32M−149Jun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Fidelity Contrafund K6265K0.49%US$3.46M−3,405Jun 30, 2026
Fidelity Small Cap Index Fund238K0.44%US$2.19MNewJul 31, 2026
Vanguard Extended Market Index Fund235K0.43%US$3.07M−851Jun 30, 2026
Fidelity Growth Company K6 Fund169K0.31%US$1.83M+45,728May 31, 2026
Fidelity Series Growth Company Fund154K0.28%US$1.67M+42,900May 31, 2026
iShares Russell 2000 Growth ETF141K0.26%US$1.84MNewJun 30, 2026
SmallCap Growth Fund I140K0.26%US$1.29M+1,146Jul 31, 2026
Franklin Biotechnology Discovery Fund127K0.24%US$1.17MNo changeJul 31, 2026
Fidelity Extended Market Index Fund110K0.20%US$1.19MNewMay 31, 2026
Schwab U.S. Small-Cap ETF99,7520.18%US$1.08MNewMay 31, 2026
iShares Micro-Cap ETF72,9880.13%US$952KNewJun 30, 2026
Small Cap Core Portfolio70,4300.13%US$919KNewJun 30, 2026
iShares Russell 2000 Value ETF63,9660.12%US$835KNewJun 30, 2026
Schwab Small-Cap Index Fund52,8950.10%US$487KNewJul 31, 2026
Fidelity Total Market Index Fund44,2800.08%US$480KNewMay 31, 2026
Health Sciences Portfolio43,1000.08%US$562KNo changeJun 30, 2026
Master Small Cap Index Series40,6890.08%US$531KNewJun 30, 2026
AB Small Cap Growth Portfolio35,1800.06%US$459K−456KJun 30, 2026
SMALLCAP World Fund32,3070.06%US$422KNewJun 30, 2026
Fidelity Series Total Market Index Fund32,2570.06%US$350KNewMay 31, 2026
Fidelity Nasdaq Composite Index Fund30,7720.06%US$334KNewMay 31, 2026
Nuveen Small Cap Blend Index Fund28,9880.05%US$267KNewJul 31, 2026
AVIP AB Small Cap Portfolio23,7960.04%US$311K−556Jun 30, 2026
EQ/2000 Managed Volatility Portfolio22,8930.04%US$299KNewJun 30, 2026
T. Rowe Price Health Sciences Portfolio20,9760.04%US$274KNo changeJun 30, 2026
LVIP State Street Small-Cap Index Fund16,2000.03%US$211KNewJun 30, 2026
Schwab U.S. Broad Market ETF15,5560.03%US$169KNewMay 31, 2026
Fidelity Small Cap Growth Index Fund14,0030.03%US$183KNewJun 30, 2026
Schwab Total Stock Market Index Fund14,0000.03%US$129KNo changeJul 31, 2026
Vanguard Balanced Index Fund11,9990.02%US$157KNo changeJun 30, 2026
Vanguard Russell 2000 Index Fund11,8720.02%US$129KNo changeMay 31, 2026
Small Cap Index Fund11,2430.02%US$147KNewJun 30, 2026
Global X Russell 2000 ETF10,3570.02%US$95,388NewJul 31, 2026
Fidelity Small Cap Value Index Fund9,4990.02%US$124KNewJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund9,4900.02%US$124KNo changeJun 30, 2026
AB Small Cap Growth Portfolio8,7390.02%US$114K+113Jun 30, 2026
MetLife Russell 2000 Index Portfolio7,7970.01%US$102KNewJun 30, 2026
ATM Small Cap Managed Volatility Portfolio7,4390.01%US$97,079NewJun 30, 2026
Health Sciences Trust7,2110.01%US$94,104No changeJun 30, 2026
ProShares Nanotechnology ETF6,7000.01%US$72,628NewMay 31, 2026

This page holds 50 of 98 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Tim Kutzkey
10% owner
Buy89,200USD 11.56US$1.03MSep 3, 2026

Big stakes

HolderStakeSharesDate
FMR LLC10.20%5.52MSep 30, 2026
James B. Tananbaum7.70%4.15MFeb 4, 2026
BlackRock Portfolio Management LLC5.50%3MMar 31, 2026
PERLMUTTER ROGER M5.20%2.89MFeb 4, 2026
Innovation Endeavors III LP5.00%2.72MMar 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Meline
Other companies: Lonza Group AG (Independent Member of the Board of Directors · Since at least May 8, 2026); HP Inc. (Director · Since at least Nov 1, 2023); Pacific Biosciences of California, Inc. (Director · Oct 13, 2023 – Jun 18, 2024 · Past); Moderna, Inc. (Chief Financial Officer · Jun 8, 2020 – Aug 9, 2022 · Past); Amgen Inc. (EVP & CFO · Jul 21, 2014 – Nov 25, 2019 · Past); TRW Automotive Holdings Corp (Director · Feb 12, 2014 – May 13, 2014 · Past); 3M Company (Former Sr. VP & CFO · Sep 2, 2008 – Apr 30, 2014 · Past)
Director · Since at least Feb 4, 2026
Roy Baynes
Other companies: Nurix Therapeutics, Inc. (Director · Since at least Mar 11, 2025); Aardvark Therapeutics, Inc. (Director · Since at least Feb 12, 2025); Natera, Inc. (Director · Since at least Jul 25, 2018); Travere Therapeutics, Inc. (Director · Since at least Jul 19, 2016); Atara Biotherapeutics, Inc. (Director · Sep 11, 2018 – Jun 23, 2022 · Past)
Chief Medical Officer · Since at least Feb 4, 2026
Robert L. Huffines
Other companies: Becton, Dickinson and Company (Director · Since at least Dec 1, 2025); Insulet Corporation (Director · Since at least Oct 23, 2025); Walgreens Boots Alliance Inc (Director · Since at least Jan 25, 2024); Solid Biosciences Inc. (Director · Jan 25, 2018 – Dec 13, 2022 · Past)
Director · Since at least Feb 4, 2026
Roger Perlmutter
Other companies: NGM Biopharmaceuticals Inc (Director · Jun 8, 2021 – Apr 5, 2024 · Past); Merck & Company, Inc. (Exe V-P & Pres, MRL · Apr 15, 2013 – May 1, 2020 · Past); Microbot Medical Inc. (Director · Dec 14, 2006 – Dec 14, 2012 · Past); Amgen Inc. (EVP, Research & Development · Apr 3, 2006 – Feb 2, 2012 · Past)
See remarks, Director · Since at least Feb 4, 2026
Ma. Fatima D. Francisco
Other companies: HP Inc. (Director · Since at least Jun 17, 2024); Procter & Gamble Company (the) (CEO - Baby, Fem & Family Care · Since at least Feb 6, 2018); Organon & Co. (Director · Jun 2, 2021 – Jun 9, 2023 · Past)
Director · Since at least Jun 8, 2026
Kenneth C Frazier
Other companies: Merck & Company, Inc. (Executive Chair, Director · Nov 3, 2009 – Nov 7, 2022 · Past); Exxon Mobil Corporation (Director · May 27, 2009 – May 25, 2022 · Past)
Director · Since at least Feb 4, 2026
Leon Chen
Other companies: Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 6, 2021 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Nov 16, 2022 · Past)
Director · Since at least Feb 4, 2026
Michael A. Klobuchar
Other companies: Revvity, Inc. (Chief Operating Officer, Eikon Therapeutics, Inc. · Since at least Feb 1, 2024); Merck & Company, Inc. (EVP - Chief Strategy Officer · Jul 5, 2021 – May 4, 2024 · Past)
Chief Operating Officer · Since at least Feb 4, 2026
Alfred BowieChief Financial Officer · Since at least Nov 2, 2026
Alfred Lloyd Bowie JrChief Financial Officer · Since at least Feb 4, 2026
All 17 people
PersonSeat
Barbara HowesChief People Officer · Since at least Nov 5, 2026
Benjamin Bruno ThornerSee Remarks · Since at least Feb 4, 2026
Ben ThornerChief Business Officer and General Counsel · Since at least Nov 4, 2026
Ching-Pin ChangExecutive Vice President and Chief Scientific Officer · Since at least Sep 3, 2026
Josh WolfeDirector · Since at least Feb 4, 2026
Mike KlobucharChief Operating Officer · Since at least Nov 4, 2026
Russ BermanChief Technology Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Eikon Therapeutics, Inc.